源流生物科学公司申请欧洲专利,申请针对NASH的SIRT6疗法,以推进其寿命和代谢性疾病管道。 Genflow Biosciences filed a European patent for a SIRT6 therapy targeting NASH, advancing its longevity and metabolic disease pipeline.

热流生物科学PLC已宣布发表其欧洲专利申请,申请采用SIRT6变异疗法,以非酒精类胃炎(NASH)为对象,以加强其长寿和新陈代谢病疗法方面的知识产权。 Genflow Biosciences PLC has announced the publication of its European patent application for a SIRT6 variant targeting non-alcoholic steatohepatitis (NASH), strengthening its intellectual property in longevity and metabolic disease therapies. 根据《专利合作条约》提出的申请提供了临时保护和最后批准后可能的追溯性损害赔偿。 The application, filed under the Patent Cooperation Treaty, provides provisional protection and potential retroactive damages upon final grant. 该公司在2025年3月开始的为期12个月的狗试验中推进其领先疗法GF-1002,计划今后为MASH(一种相关的肝脏病)制定临床方案。 The company, which is advancing its lead therapy GF-1002 in a 12-month dog trial starting in March 2025, plans future clinical programs for MASH, a related liver condition. 以联合王国为基地,在比利时进行研发,Genflow是欧洲唯一公开交易的长寿公司。 Based in the UK with R&D in Belgium, Genflow is the only publicly traded longevity-focused company in Europe.